Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02879175
Active, not recruiting Observational

Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms

NCT02879175 · tracked via the Priya Life Science France tracker
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Started
2016-09-08
Last updated
2026-01-20

Condition(s) studied

Intracranial Aneurysms

Study summary

After endovascular treatment of the intracranial aneurysm, recanalization may occur, with a risk of recurrent subarachnoid haemorrhage or long-term angiographic recurrences of aneurysms.

Few data exist on patients' long-term follow-up after subarachnoid haemorrhage caused by ruptured intracranial aneurysms.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: \- Patient treated with embolization for SAH due to aneurysmal rupture Exclusion Criteria: \- Patient refusal to participate in the study

Primary outcome measure(s)

  • early neurological clinical recovery — 1 year after Subarachnoid Haemorrhage
    modified Rankin scale

Trial sites (1)

FacilityCityRegionStatus
Fondation Opthalmologique A de Rothschild Paris France

More Fondation Ophtalmologique Adolphe de Rothschild trials in France

Cardiac Involvement in Wilson's Disease Recruiting
Identifying New Genetic Causes to Development Disorders Recruiting
Optimization of Sequences to Improve the Quality and Comfort of the Magnetic Resonance Imaging Examination Recruiting
Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation Recruiting
RESting-state Functional MRI for Prediction of Post-surgical Prognosis In Pediatric Drug-Resistant Epilepsy Recruiting

Other trials for the same condition

Post-Market Product Surveillance of Intracranial ANeurysms Treated With Commercial ReGistered ACANDIS Devices in FrancE Recruiting
Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN Active, not recruiting
Risk Analysis of Intracranial Aneurysm Rupture Through Social Determinants of Health Active, not recruiting
PMCF Registry to Describe the Safety and Performance of p64, p48 MW and p64 MW in France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02879175 on ClinicalTrials.gov ↗ ← All trials in France